Elekta to acquire Nucletron, complementing its product offering with world-leading brachytherapy technology

Elekta to acquire Nucletron, complementing its product offering with
world-leading brachytherapy technology

Press Release
Stockholm, Sweden, June 21, 2011

Elekta has agreed to acquire Nucletron for EUR 365 million in cash. The
acquisition is expected to be accretive to Elekta's cash earnings within
twelve months. The transaction remains subject to regulatory approval
and is expected to close in early autumn 2011.
Through this compelling combination Elekta will offer a complete range
of radiotherapy planning and delivery technologies, enhancing its
combined ability to meet the clinical needs of cancer patients and
health care providers throughout the world.

Elekta today announced the signing of a definitive agreement to acquire
Nucletron, the world leader in brachytherapy treatment planning and
delivery. Nucletron is the global market leader in brachytherapy with
2010 reported revenues of EUR 128 million and EBITDA of EUR 26 million.

Nucletron will add 1,000 new customers to Elekta's customer base of more
than 5,000. The two companies have highly synergistic product and
technology portfolios. The combination will lead to enhanced solutions
for customers and patients, and will allow the enlarged group to take
mutual advantage of Nucletron's expertise in brachytherapy combined with
Elekta's global presence, particularly in emerging markets.

Under the terms of the agreement, Elekta will pay cash consideration of
EUR 365 million to acquire Nucletron on a cash and debt-free basis. The
transaction, which has been approved by the Board of Directors of both
companies, is subject to regulatory approval and is expected to close in
early autumn 2011.

The acquisition is expected to be accretive to Elekta's cash earnings
within twelve months. The transaction will be financed through existing
cash on hand and available credit facilities. The proforma business will
continue to have a strong financial profile.

“Elekta and Nucletron have a long history of collaboration. Nucletron
has a very talented team and the company has created a truly market
leading business. The combination creates an excellent opportunity for
our patients, customers, employees and shareholders.” said Elekta
President and CEO Tomas Puusepp. “The combination with Nucletron
enhances Elekta's product portfolio, offers significant opportunities
and extends our geographic reach and distribution capacity.”

“This integrated product portfolio is particularly important, as the
combination of brachytherapy and external beam radiation therapy
treatments continues to emerge as a leading course of therapy for cancer
worldwide,” he added.

“By joining forces with Elekta, Nucletron becomes part of a world
leading provider of therapy for many types of cancers. I believe the
combination represents a unique opportunity to realize Nucletron's true
potential, gain critical mass and continue to invest in the development
of brachytherapy. We look forward to working with our new colleagues”,
said Nucletron CEO Jos Lamers.

BofA Merrill Lynch served as Elekta's exclusive financial advisor on the
transaction, and NautaDutilh served as its legal counsel. Jefferies
International served as exclusive financial advisor to Nucletron. Allen
& Overy served as Nucletron's legal counsel.

For questions please contact:
Stina Thorman, Vice President Corporate Communications at +46 8 587
25437.

Elekta hereby invites analysts and media to a web and telephone
conference at 10.00 CET, Please register on
http://webeventservices.stream57.com/20062011elekta/ (http://webeventser
vices.stream57.com/20062011elekta/)

It will also be possible to dial in and listen to this event: Password:
898145

Swedish dial-in number: +46 (0)8 505 20 110
Dial-in number the Netherlands: +31 (0)20 7965 008
UK dial-in number: +44 (0)20 7162 0077
US dial-in number: +1 334 323 6201

A replay of the event will be available until June 28, 2011. Please use
the same link as above or call the numbers below and give the access
code 898145.

Swedish replay number: +46 (0)8 505 203 33
UK replay number: +44 (0) 207 031 4064
US replay number: +1 954 334 0342
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 07.00 CET on
June 21, 2011.